Multicenter phase 2 study of induction chemotherapy with docetaxel and nedaplatin for oral squamous cell carcinoma
- 116 Downloads
To determine the clinical and hisotological efficacy and toxicities of induction chemotherapy with docetaxel (DOC) and nedaplatin (CDGP) for oral squamous cell carcinoma (OSCC) in the preoperative setting.
A total of 30 patients with locally advanced but operable OSCC were enrolled. Combination induction chemotherapy consisted of DOC 60 mg/m2 followed by CDGP 100 mg/m2.
All patients received one cycle of chemotherapy. In the clinical assessment, ten patients achieved partial response for an overall response rate of 33.3% (95% CI, 16.4–50.2%). Histological assessment of surgical specimens showed an overall response rate of 56.6% (95% CI, 38.9–74.3%). Although severe neutropenia was observed in 90% of patients, only one patient (3.3%) experienced severe infection. Toxicities associated with this regimen did not interfere with planned radical surgery.
A single cycle of preoperative combination chemotherapy with DOC and CDGP showed moderate histological activity with an acceptable safety profile for the planned radical surgery. Further studies testing more cycles before surgery might be more appropriate.
KeywordsNeoadjuvant chemotherapy Squamous cell carcinoma Docetaxel Nedaplatin Oral cancer
- 1.Verwij J, de Jong PC, de Mulder MPH, van der Broek P, Alexieva-Figusch J, van Putten WL et al (1989) Induction chemotherapy with cisplatin and continuous infusion 5-fluorouracil in locally far-advanced head and neck cancer. Am J Clin Oncol 12:420–424Google Scholar
- 2.Argiris A, Jayaram P, Pichardo D (2005) Revisiting induction chemotherapy for head and neck cancer. Oncology (Williston Park) 19:759–770Google Scholar
- 4.Al-Kourainy K, Kish J, Ensley J, Tapazoglou E, Jacobs J, Weaver A et al (1987) Achievement of superior survival for histologically negative versus histologically positive clinically complete responders to cisplatin combination in patients with locally advanced head and neck cancer. Cancer 59:233–238CrossRefPubMedGoogle Scholar
- 5.Adjuvant chemotherapy for advanced head and neck squamous carcinoma (1987) Final report of the Head and Neck Contracts Program. Cancer 60:301–311Google Scholar
- 6.Ensley J, Crissman J, Kish J, Jacobs J, Weaver A, Kinzie J et al (1986) The impact of conventional morphologic analysis on response rates and survival in patients with advanced head and neck cancers treated initially with cisplatin-containing combination chemotherapy. Cancer 57:711–717CrossRefPubMedGoogle Scholar
- 7.Hitt R, López-Pousa A, Martínez-Trufero J, Escrig V, Carles J, Rizo A et al (2005) Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 23:8636–8645CrossRefPubMedGoogle Scholar
- 13.Sobin LH, Wittenkind CH (eds) (2002) TNM classification of malignant tumors, 6th edn. Wiley and Sons, New YorkGoogle Scholar
- 14.Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al (2000) New guidelines to evaluate the response of treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States. National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216CrossRefPubMedGoogle Scholar
- 15.Shimosato Y, Oboshi S, Baba K (1971) Histological evaluation of effects of radiotherapy and chemotherapy for carcinomas. Jpn J Clin Oncol 1:19–35Google Scholar
- 18.Ebihara S, Fujii H, Sasaki Y et al (1997) A late phase II study of docetaxel (Taxotere) in patients with head and neck cancer (HNC). In: Proc Am Soc Clin Oncol 399a (Abstr 1425)Google Scholar
- 19.Couteau C, Leyvraz S, Outlid-Aissa D et al (1996) A phase II study of docetaxol in squamous cell carcinoma (SCC) of the head and neck. Proc Am Soc Clin Oncol 15:315 (Abst 889)Google Scholar
- 21.Alberts DS, Fanta PT, Ruuing KL, Adair LP Jr, Garcia DJ, Liu-Stevens R et al (1997) In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human ovarian cancers. Cancer Chemother Pharmacol 39:493–497CrossRefPubMedGoogle Scholar
- 23.Inuyama Y, Miyake H, Horiuchi M, Hayasaki K, Komiyama S, Ota K (1992) A late phase II clinical study of cis-diamine glycolato platinum, 254-S, for head and neck cancers. Gan To KagakuRyoho 19:871–877Google Scholar
- 28.Caponigro F, Massa E, Manzione L, Rosati G, Rosati G, Biglietto M, De Lucia L et al (2001) Docetaxel and cisplatin in locally advanced or metastatic squamous-cell carcinoma of the head and neck: a phase II study of the southern Italy cooperating oncology group (SICOG). Ann Oncol 12:199–202CrossRefPubMedGoogle Scholar
- 34.Vokes E, Wechselbaum R, Mick R, McEvilly JM, Haraf DJ, Panje WR (1992) Favorable long-term survival following induction chemotherapy with cisplatin, fluorouracil and leucovorin and concomitant chemoradiotherapy for locally advanced head and neck cancer. J Natl Cancer Inst 84:877–882CrossRefPubMedGoogle Scholar
- 35.Gibson MK, Li Y, Murphy B, Hussain MH, DeConti RC, Ensley J et al (2005) Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an Intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol 23:3562–3567CrossRefPubMedGoogle Scholar
- 36.Fujta Y, Hiramatsu M, Kawai M, Sumiyoshi K, Nishimura H, Tanigawa N (2008) Evaluation of combined docetaxel and nedaplatin chemotherapy for recurrent esophageal cancer compared with conventional chemotherapy using cisplatin and 5-fluorouracil: a pilot study. Dis Esophagus 21:496–501CrossRefGoogle Scholar